German pharmaceutical company Bayer (BAYRY) is keeping with its plan to raise $19 billion in equity before it dives into a rights and bonds issue, in regard to its planned $57 billion acquisition of U.S. seeds maker Monsanto, (MON) the Wall Street Journal reports.

Bayer wants to do the equity first, before jumping into the bond market, company CFO Johannes Dietsch explained to analysts on a call. Bayer believes the deal will pass regulatory barriers, despite delays by U.S. and European antitrust authorities.